

International Nonproprietary Names for Pharmaceutical Substances (INN)

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 70 Proposed INN not later than 30 June 1994**.

Proposed International Nonproprietary Names: List 70

Lists of proposed (1-65) and recommended (1-31) international nonproprietary names can be found in Cumulative List No. 8, 1992.

*Proposed International
Nonproprietary Name
(Latin, English)*


*Chemical Name or Description; Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use**

abciximabum
abciximab

immunoglobulin G (human-mouse monoclonal c7E3 clone p7E3V_HhC_{γ4} Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3V_KhC_K light chain
143653-53-6 *antithrombotic*


acidum incadronicum
incadronic acid

[(cycloheptylamino)methylene]diphosphonic acid
C₈H₁₉NO₆P₂ 124351-85-5 *calcium regulator*



adatanserinum
adatanserin


N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-1-adamantanecarboxamide
C₂₁H₃₁N₅O 127266-56-2 *serotonin receptor antagonist*



***Action and Use:** The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will be neither revised nor included in the Cumulative Lists of INNs.

adelmidrolum
adelmidrol

N,N'-bis(2-hydroxyethyl)nonanediamide
 $C_{13}H_{26}N_2O_4$ 1675-66-7 *antiacne agent*




afovirsenum
afovirsen

2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioguanilyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioadenylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thioguanilyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-thymidine
 $C_{192}H_{250}N_{57}O_{107}P_{19}S_{19}$ *antiviral*


aglepristonum
aglepristone

11β-[*p*-(dimethylamino)phenyl]-17β-hydroxy-17-[(*Z*)-propenyl]estra-4,9-dien-3-one
 $C_{29}H_{37}NO_2$ 124478-60-0 *abortive (vet.)*




alnespironum
alnespirone

(+)-(S)-*N*-[4-[(5-methoxy-3-chromanyl)propylamino]butyl]-1,1-cyclopentanediacet-
timide
 $C_{26}H_{38}N_2O_4$ 138298-79-0 *antidepressant*



arteflenum
arteflene

(1*S*,4*R*,5*R*,8*S*)-4-[(*Z*)-2,4-bis(trifluoromethyl)styryl]-4,8-dimethyl-
2,3-dioxabicyclo[3.3.1]nonan-7-one
 $C_{19}H_{18}F_6O_3$ 123407-36-3 *antimalarial*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


batimastatum
batimastat

(2*S*,3*R*)-5-methyl-3-[[[(α , α)-(methylcarbamoyl)phenethyl]carbamoyl]-2-
[[2-(thienylthio)methyl]hexanohydroxamic acid
 $C_{23}H_{31}N_3O_4S_2$ 130370-60-4 *antineoplastic*




besipirdinum
besipirdine

1-(propyl-4-pyridylamino)indole
 $C_{16}H_{17}N_3$ 119257-34-0 *nootropic agent*




bicalutamidum
bicalutamide

($\pm$)-4'-cyano- α , α , α -trifluoro-3-[(*p*-fluorophenyl)sulfonyl]-2-methyl-*m*-lactotoluidide
 $C_{18}H_{14}F_4N_2O_4S$ 90357-06-5 *antiandrogen*




bosentanum
bosentan

p-*tert*-butyl-*N*-[6-(2-hydroxyethoxy)-5-(*o*-methoxyphenoxy)-2-(2-pyrimidinyl)-
4-pyrimidinyl]benzenesulfonamide
 $C_{27}H_{29}N_5O_6S$ 147536-97-8 *endothelin receptor antagonist*



candocuronii iodidum
candocuronium iodide

17 α ,17 α -dimethyl-3 β -(1-methylpyrrolidinio)-17 α -azonia-*D*-homoandrost-5-ene
diiodide
 $C_{26}H_{46}I_2N_2$ 54278-85-2 *neuromuscular receptor antagonist*



capromabum
capromab


immunoglobulin G 1 (mouse monoclonal 7E11-C5.3 anti-human prostatic carcinoma
cell), disulfide with mouse monoclonal 7E11-C5.3 light chain, dimer
151763-64-3 *diagnostic agent*

certoparinum natricum
certoparin sodium

Sodium salt of depolymerized heparin obtained by isoamyl nitrite degradation of heparin from pork intestinal mucosa; the majority of the components have a 2-*O*-sulfo- α -L-idopyranosuronic acid structure at the non reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannose structure at the reducing end of their chain; the average relative molecular mass is 5000 to 7000; at least 70 per cent less than 10 000: the degree of sulfatation is 2 to 2,5 per disacchardic unit.
anticoagulant


cinalukastum
cinalukast

3'-[(*E*)-2-(4-cyclobutyl-2-thiazolyl)vinyl]-2,2-diethylsuccinanilic acid
 $C_{23}H_{29}N_2O_3S$ 128312-51-6
antiasthmatic




dapabutanum
dapabutan

($\pm$)-3-[[3-(dodecylamino)propyl]amino]butyric acid
 $C_{19}H_{40}N_2O_2$ 6582-31-6
antiseptic




darifenacinum
darifenacin

(*S*)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]- α,α -diphenyl-3-pyrrolidineacetamide
 $C_{28}H_{30}N_2O_2$ 133099-04-4
muscarin receptor antagonist



denotivirum
denotivir

5-benzamido-4'-chloro-3-methyl-4-isothiazolecarboxanilide
 $C_{18}H_{14}ClN_3O_2S$ 51287-57-1
antiviral




desirudinum
desirudin

63-desulfohirudin (*Hirudo medicinalis* isoform HV2)
 $C_{287}H_{440}N_{80}O_{110}S_6$ 120993-53-5
anticoagulant

desmeninolum
desmeninol

($\pm$)-2-hydroxy-4-(methylthio)butyric acid
 $C_5H_{10}O_3S$ 120-91-2
amino acid analogue



detumomabum
detumomab

immunoglobulin (mouse monoclonal SPECIFID anti-human B lymphoma cell)
disulfide with mouse monoclonal SPECIFID light chain, dimer
145832-33-3
immunomodulator


Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

dexketoprofenum
dexketoprofen

(+)-(S)-*m*-benzoylhydrotropic acid
C₁₆H₁₄O₃ 22161-81-5

*non-steroidal anti-inflammatory,
analgesic*



dornasum alfa
dornase alfa


deoxyribonuclease (human clone 18-1 protein moiety)
C₁₃₂₁H₁₆₉₃N₃₃₉O₃₉₆S₉ 143831-71-4

enzyme

elopiprazolum
elopiprazole

1-(7-benzofuranyl)-4-[[5-(*p*-fluorophenyl)pyrrol-2-yl]methyl]piperazine
C₂₃H₂₂FN₃O 115464-77-2

antipsychotic



emideltidum
emideltide

L-tryptophyl-L-alanylglycylglycyl-L- α -aspartyl-L-alanyl-L-serylglycyl-L-glutamic acid
C₃₅H₄₉N₁₀O₁₅ 62568-57-4

sedative

H-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-OH

enlimomabum
enlimomab


immunoglobulin G 2a (mouse monoclonal BI-RR-1 anti-human-antigen CD 54),
disulfide with mouse monoclonal BI-RR-1 light chain, dimer
142864-19-5

immunomodulator

geclosporinum
geclosporin


cyclo[[[(2*S*,3*R*,4*R*,6*E*)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-norvalyl-L-methylglycyl-L-methyl-L-leucyl-L-valyl-L-methyl-L-leucyl-L-alanyl-L-alanyl-L-methyl-L-leucyl-L-methyl-L-leucyl-L-valyl]
C₆₃H₁₁₃N₁₁O₁₂ 74436-00-3

immunosuppressant




glenvastatinum
glenvastatin

(4*R*,6*S*)-6-[(*E*)-2-[4-(*p*-fluorophenyl)-2-isopropyl-6-phenyl-3-pyridyl]vinyl]tetra-
hydro-4-hydroxy-2*H*-pyran-2-one
C₂₇H₂₆FO₃ 122254-45-9 *antihyperlipidaemic*




icometasonii enbutas
icometasone enbutate

9-chloro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-butyrate
21-acetate
C₂₈H₃₇ClO₇ 103466-73-5 *corticosteroid*




iganidipinum
iganidipine

(±)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-
(*m*-nitrophenyl)-3,5-pyridinedicarboxylate
C₂₈H₃₈N₄O₆ 119687-33-1 *calcium channel blocker*




ilepcimidum
ilepcimide

1-[(*E*)-3,4-(methylenedioxy)cinnamoyl]piperidine
C₁₅H₁₇NO₃ 82857-82-7 *anticonvulsant*




ilonidapum
ilonidap

6-chloro-5-fluoro-3-[(*Z*)-α-hydroxy-2-thenylidene]-2-oxo-1-indolinecarboxamide
C₁₄H₈ClFN₂O₃S 135202-79-8 *non-steroidal anti-inflammatory*




imitrodastum
imitrodast

4,5-dihydro-2-(imidazol-1-ylmethyl)benzo[b]thiophene-6-carboxylic acid
 $C_{13}H_{12}N_2O_2S$ 114686-12-3
antithrombotic, thromboxane A_2 synthetase inhibitor




iralukastum
iralukast

7-[(1*S*,2*E*,4*Z*)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-[(α *F*)- α -hydroxy-*m*-(trifluoromethyl)benzyl]-2,4-nonadienyl]thio]-4-oxo-4*H*-1-benzopyran-2-carboxylic acid
 $C_{38}H_{37}F_3O_8S$ 151581-24-7
antithrombotic




laflunimusum
laflunimus

(*Z*)- α -cyano- α^4, α^4 -trifluoro- β -hydroxycyclopropaneacrylo-3',4'-xylidide
 $C_{15}H_{13}F_3N_2O_2$ 147076-36-6
immunodepressant




lafutidinum
lafutidine

($\pm$)-2-(furfurylsulfinyl)-*N*-[(*Z*)-4-[[4-(piperidinomethyl)-2-pyridyl]oxy]-2-butenyl]-acetamide
 $C_{22}H_{26}N_3O_4S$ 118288-08-7
histamine H_2 -receptor antagonist




laurecetii bromidum
laurecetium bromide

(carboxymethyl)dodecyltrimethylammonium bromide, ethyl ester
 $C_{18}H_{36}BrNO_2$ 1794-75-8
antiseptic



lecimibidum
lecimibide

3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenylimidazol-2-yl)thio]pentyl]-1-heptylurea
 $C_{34}H_{40}F_2N_4OS$ 130804-35-2
antihyperlipidaemic




ledismasum
ledismase

superoxide dismutase (human copper-zinc subunit), cyclic (57→146)-disulfide, dimer
 $C_{679}H_{1063}N_{203}O_{224}S_4$ 149394-67-2 enzyme


lemoxinolium
lemoxinol

α -(4,6-dichloro-*m*-tolyl)oxy- ω -hydroxypoly(oxyethylene)
Each *lemoxinol* name is followed by a number indicating the approximate number of oxyethylene groups present, e.g. *lemoxinol 5*, and the individual chemical names may contain a specific numerical syllable for the same purpose
 $C_7H_6OCl_2(C_2H_4O)_n$ antiseptic




letrozolum
letrozole

4,4'-(1*H*-1,2,4-triazol-1-ylmethylene)dibenzonitrile
 $C_{17}H_{11}N_5$ 112809-51-5 antineoplastic




lexipafantum
lexipafant

N-methyl-*N*-[[α -(2-methyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)-*p*-tolyl]sulfonyl]-*L*-leucine, ethyl ester
 $C_{23}H_{30}N_4O_4S$ 139133-26-9 platelet activating factor antagonist




lopobutanum
lopobutan

($\pm$)-3-[[3-(dodecyloxy)propyl]amino]butyric acid
 $C_{19}H_{39}NO_3$ 6582-30-5 antiseptic



loviridum
loviride

($\pm$)-2-(6-acetyl-*m*-toluidino)-2-(2,6-dichlorophenyl)acetamide
 $C_{17}H_{16}Cl_2N_2O_2$ 147362-57-0 antiviral




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


lubeluzolum
lubeluzole

(+)-(S)-4-(2-benzothiazolylmethylamino)- α -[(3,4-difluorophenoxy)methyl]-
1-piperidineethanol
 $C_{22}H_{25}F_2N_3O_2S$ 144665-07-6 *neural protective agent*




mofarotenun
mofarotene

4-[2-[p-(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl]=
phenoxy]ethylmorpholine
 $C_{29}H_{39}NO_2$ 125533-88-2 *antineoplastic*




nupafantum
nupafant

N-[(S)-1-(ethoxymethyl)-3-methylbutyl]-N-methyl- α -(2-methyl-1H-
imidazo[4,5-c]pyridin-1-yl)-p-toluenesulfonamide
 $C_{23}H_{32}N_4O_3S$ 139133-27-0 *platelet activating factor antagonist*




olprinonum
olprinone

1,2-dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxonicotinonitrile
 $C_{14}H_{13}N_3O$ 106730-54-5 *cardiac stimulant, vasodilator*




oxeclosporinum
oxeclosporin

cyclo[[[(2*S*,3*R*,4*R*,6*E*)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyl]-*N*-methylglycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl-L-alanyl-*O*-(2-hydroxyethyl)-D-seryl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl]
C₆₄H₁₁₅N₁₁O₁₄ 135548-15-1 immunosuppressant




pamicrogrelum
pamicrogel

ethyl 2-[4,5-bis(*p*-methoxyphenyl)-2-thiazolyl]pyrrole-1-acetate
C₂₅H₂₄N₂O₄S 101001-34-7 platelet aggregation inhibitor



pazinaclonum
pazinaclone


(±)-8-[[2-(7-chloro-1,8-naphthyridin-2-yl)-3-oxo-1-isoindolinyl]acetyl]-1,4-dioxo-8-azaspiro[4.5]decane
C₂₅H₂₃ClN₄O₄ 103255-66-9 anxiolytic



and enantiomer

pobilukastum
pobilukast

(2*S*,3*R*)-3-[(2-carboxyethyl)thio]-3-[*o*-(8-phenyloctyl)phenyl]lactic acid
C₂₆H₃₄O₅S 107023-41-6 antiasthmatic, leukotriene receptor antagonist




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


polixetonii chloridum
polixetonium chloride

poly[oxyethylene(dimethyliminio)ethylene(dimethyliminio)ethylene dichloride]
(C₁₀H₂₄Cl₂N₂O)_n 31512-74-0 *disinfectant*




ramosetronum
ramosetron

(-)-(R)-1-methylindol-3-yl 4,5,6,7-tetrahydro-5-benzimidazolyl ketone
C₁₇H₁₇N₃O 132036-88-5 *serotonin receptor antagonist*




rasagilinum
rasagiline

(R)-N-2-propynyl-1-indanamine
C₁₂H₁₃N 136236-51-6 *antiparkinsonian*




ricasetronum
ricasetron

3,3-dimethyl-N-1 α H,5 α H-tropan-3 α -yl-1-indolinecarboxamide
C₁₉H₂₇N₃O 117086-68-7 *serotonin receptor antagonist*




seratrodastum
seratrodast

($\pm$)-2,4,5-trimethyl-3,6-dioxo- ζ -phenyl-1,4-cyclohexadiene-1-heptanoic acid
C₂₂H₂₆O₄ 112665-43-7 *antiasthmatic, thromboxane A₂ receptor antagonist*




spiroglumidum
spiroglumide

(R)- γ -(3,5-dichlorobenzamido)- δ -oxo-8-azaspiro[4.5]decane-8-valeric acid
C₂₁H₂₅Cl₂N₂O₄ 137795-35-8 *antiulcer*




sprodiamidum
sprodiamide

aqua[*N,N*-bis[2-[(carboxymethyl)][(methylcarbamoyl)methyl]amino]ethyl]=
glycinato(3-)]dysprosium, hydrate
 $C_{16}H_{28}DyN_5O_9 \cdot xH_2O$ 138721-73-0 *diagnostic aid*




technetium (^{99m}Tc) furifosminum
technetium (^{99m}Tc) furifosmin

(OC-6-13)-[[4,4'-(ethylenebis(nitrilomethylidyne)]bis[dihydro-2,2,5,5-tetramethyl-3(2*H*)-furanonato]](2-)-*N,N',O^3,O^3*]bis[tris(3-methoxypropyl)phosphine-*P*][^{99m}Tc]=
technetium(1+) chloride
 $C_{44}H_{84}ClN_2O_{10}P_2^{99m}Tc$ 142481-95-6 *radiocontrast medium*



telmisartanum
telmisartan

4'-[[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-
2-biphenylcarboxylic acid
 $C_{33}H_{30}N_4O_2$ 144701-48-4 *angiotensin II receptor antagonist*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description; Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


temoporfinum
temoporphin

3,3',3'',3'''-(7,8-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
 $C_{44}H_{32}N_4O_4$ 122341-38-2 *photosensitizer*




tisartanum
tisartan

1-[[N-[p-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]valeramido]methyl]-1-cyclopentane=carboxylic acid
 $C_{26}H_{31}N_5O_3$ 137882-98-5 *angiotensin II receptor antagonist*




tolafentrinum
tolafentrine

(-)-4'-(*cis*-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[*c*][1,6]=naphthyridin-6-yl)-*p*-toluenesulfonanilide
 $C_{28}H_{31}N_3O_4S$ 139308-65-9 *phosphodiesterase-inhibitor*



tradecamidum
tradecamide

13-hydroxy-*N,N*-dimethyltridecanamide
 $C_{15}H_{31}NO_2$ 132787-19-0 *antiacne agent*




votumumabum
votumumab

immunoglobulin G3 (human monoclonal 88-BV59 heavy chain anti-human carcinoma-associated antigen), disulfide with human monoclonal 88-BV59 κ -chain, dimer

148189-70-2 *diagnostic agent*


xanomelinum
xanomeline

3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridine
 $C_{14}H_{23}N_3OS$ 131986-45-3 *cholinergic*




zankirenum
zankiren

(S)-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-α-[(αS)-α-
[[[(4-methyl-1-piperazinyl)sulfonyl]methyl]hydrocinnamido]-4-thiazole=
propionamide
 $C_{35}H_{55}N_5O_6S_2$ 138742-43-5 antihypertensive



zolasartanum
zolasartan

1-[[[3-bromo-2-(o-1H-tetrazol-5-ylphenyl)-5-benzofuranyl]methyl]-2-butyl-4-
chloroimidazole-5-carboxylic acid
 $C_{24}H_{20}BrClN_6O_3$ 145781-32-4 angiotensin II receptor antagonist




Names for Radicals and Groups

Some substances for which a proposed international nonproprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals and groups have been devised or selected, and they are suggested for use with the proposed international nonproprietary names.


dapropas
dapropate

N,N-dimethyl-β-alanine
 $C_5H_{10}NO_2$




edaminum
edamine

ethylene diamine
 $C_2H_8N_2$



fostedatum
fostedate

tetradecyl hydrogen phosphate
 $C_{14}H_{30}O_4P$



AMENDMENTS TO PREVIOUS LISTS


Supplement to WHO Chronicle Vol. 36, No. 5, 1982

Proposed International Nonproprietary Names (Prop. INN): List 48

p. 14 mitindomidum
 mitindomide

replace the chemical name, and the graphic formula by the following:

(1*R**,2*S**,3*R**,4*S**,5*R**,6*S**,7*S**,8*R**)-tricyclo[4.2.2.0^{2,5}]dec-9-ene-3,4,7,8-tetracarboxylic 3,4:7,8-diimide




WHO Drug Information, Vol. 4, No. 2, 1990

Proposed International Nonproprietary Names (Prop. INN): List 63

p. 6 gadodiamidum
 gadodiamide

replace the chemical name, CAS registry number, the molecular formula and the graphic formula by the following:

[*N,N*-bis[2-[(carboxymethyl)[methylcarbamoyl]methyl]amino]ethyl]glycinato=(3-)]gadolinium
C₁₆H₂₆GdN₅O₈ 131410-48-5



WHO Drug Information, Vol. 4, No. 4, 1990

Proposed International Nonproprietary Names (Prop. INN): List 64

p. 12 gadoterdolum
 gadoteridol

replace the chemical name by the following:

(±)-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato= [(3-)]gadolinium

WHO Drug Information, Vol. 6, No. 2, 1992

Proposed International Nonproprietary Names (Prop. INN): List 67

p. 12 pendetidum
 pendetide

add the following CAS registry number:

148805-91-8


Proposed International Nonproprietary Names (Prop. INN): List 68

p 7 igmesinum
igmesine

replace the action and use statement by the following:
σ ligand

p 15 docetaxelum
docetaxel

replace the chemical name, CAS registry number and the graphic formula by the following:
(2*R*,3*S*)-*N*-carboxy-3-phenylisoserine, *N*-*tert*-butyl ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate
148408-66-6



Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN lists only.